You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

CLINICAL TRIALS PROFILE FOR RESCRIPTOR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Rescriptor

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002210 ↗ A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies Completed Pharmacia and Upjohn Phase 2 1969-12-31 The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.
NCT00002211 ↗ Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients Completed Pharmacia and Upjohn N/A 1969-12-31 The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).
NCT00002400 ↗ A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients Completed Pharmacia and Upjohn N/A 1969-12-31 The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with other drugs.
NCT00002401 ↗ A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients Completed Pharmacia and Upjohn N/A 1969-12-31 The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients. The drugs to be used in combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rescriptor

Condition Name

Condition Name for Rescriptor
Intervention Trials
HIV Infections 6
HIV-1 Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rescriptor
Intervention Trials
HIV Infections 7
Acquired Immunodeficiency Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rescriptor

Trials by Country

Trials by Country for Rescriptor
Location Trials
United States 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rescriptor
Location Trials
New Jersey 4
California 2
New York 1
Missouri 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rescriptor

Clinical Trial Phase

Clinical Trial Phase for Rescriptor
Clinical Trial Phase Trials
Phase 2/Phase 3 1
Phase 2 2
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rescriptor
Clinical Trial Phase Trials
Completed 6
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rescriptor

Sponsor Name

Sponsor Name for Rescriptor
Sponsor Trials
Pharmacia and Upjohn 5
Triangle Pharmaceuticals 1
Bristol-Myers Squibb 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rescriptor
Sponsor Trials
Industry 8
NIH 2
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for RESCRIPTOR

Last updated: January 1, 2025

Introduction to RESCRIPTOR

RESCRIPTOR, also known as delavirdine, is an antiretroviral drug used in the treatment of HIV-1 infection. It belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and is indicated for use in combination with other antiretroviral agents.

Clinical Trials Overview

Efficacy and Safety Studies

Clinical studies evaluating RESCRIPTOR have shown mixed results. In studies comparing regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) to RESCRIPTOR plus two NRTIs, the proportion of patients achieving and sustaining an HIV-1 RNA level <400 copies/mL over one year of therapy was relatively low. For instance, in studies 21 Part II and 13C, the efficacy was evaluated by the percentage of patients with a plasma HIV-1 RNA level <400 copies/mL through Week 52. The results showed that while there was some suppression of the virus, the rates of virologic failure and discontinuation due to adverse events were significant[4].

Resistance and Cross-Resistance

RESCRIPTOR can lead to the rapid emergence of resistant virus when used as monotherapy, highlighting the importance of using it in combination with other antiretroviral agents. Mutations at amino acid positions 103 and 181 have been commonly observed in resistant isolates, which can confer cross-resistance to other NNRTIs[4].

Market Analysis

Global Antiviral Drugs Market

The global antiviral drugs market, which includes RESCRIPTOR, was estimated at USD 72.84 billion in 2022. However, this market is expected to decline at a compound annual growth rate (CAGR) of -1.99% from 2023 to 2030, primarily due to the post-COVID-19 demand reduction and the introduction of generic versions of antiviral medicines[5].

Segmental Analysis

Drug Class

Reverse transcriptase inhibitors, the class to which RESCRIPTOR belongs, dominated the antiviral drugs market with a share of 38.52% in 2022. This is due to their effectiveness in slowing down or preventing viral infections[5].

Regional Market

North America accounted for the largest share of the antiviral drugs market in 2022, with 41.51% of the market share. This is attributed to the launch of effective products and technologically advanced production facilities in the region[5].

Market Projections

Declining Market Trend

Despite the overall decline in the antiviral drugs market, there are factors that could positively impact the market for RESCRIPTOR and similar drugs. The increasing prevalence of viral diseases and growing awareness about the availability of various vaccines and treatments are expected to have a positive impact on market growth during the forecast period[5].

Competitive Landscape

The market for antiviral drugs, including RESCRIPTOR, is highly competitive with several pharmaceutical companies investing in research and development to improve their drug portfolios. Strategic partnerships among manufacturers and companies for developing novel therapeutics are anticipated to drive market growth, although the specific impact on RESCRIPTOR may be limited due to its established position and the emergence of newer treatments[5].

Future Outlook for RESCRIPTOR

Challenges

RESCRIPTOR faces significant challenges, including the emergence of resistance and the availability of newer, more effective antiretroviral therapies. For example, the recent Phase 2 data from Gilead and Merck on the investigational combination of islatravir and lenacapavir, which has the potential to become the first weekly oral HIV treatment, may further shift the market landscape away from traditional NNRTIs like RESCRIPTOR[1].

Opportunities

Despite these challenges, there remains a need for effective antiretroviral therapies, especially in regions where access to newer treatments is limited. RESCRIPTOR, as part of a combination therapy, can still play a role in managing HIV-1 infection in these settings.

Key Takeaways

  • Clinical Trials: RESCRIPTOR has shown mixed efficacy and safety profiles in clinical studies, with significant rates of virologic failure and resistance.
  • Market Analysis: The global antiviral drugs market is declining, but reverse transcriptase inhibitors remain a dominant class.
  • Market Projections: The market for RESCRIPTOR is expected to decline due to the emergence of newer treatments and generic versions.
  • Future Outlook: RESCRIPTOR may still have a role in managing HIV-1 infection, especially in regions with limited access to newer therapies.

FAQs

What is RESCRIPTOR used for?

RESCRIPTOR (delavirdine) is used in the treatment of HIV-1 infection in combination with other antiretroviral agents.

Why is RESCRIPTOR often used in combination therapy?

RESCRIPTOR should always be administered in combination with other antiretroviral agents because it can lead to the rapid emergence of resistant virus when used as monotherapy[4].

What are the common mutations associated with RESCRIPTOR resistance?

Mutations at amino acid positions 103 and 181 are commonly observed in resistant isolates, which can confer cross-resistance to other NNRTIs[4].

How is the global antiviral drugs market expected to grow?

The global antiviral drugs market is expected to decline at a CAGR of -1.99% from 2023 to 2030 due to post-COVID-19 demand reduction and the introduction of generic versions of antiviral medicines[5].

What are the regional market trends for antiviral drugs?

North America accounts for the largest share of the antiviral drugs market, driven by the launch of effective products and technologically advanced production facilities[5].

Sources

  1. Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48. Merck.
  2. HIV Drugs Market Size to Achieve USD 66.16 Billion by 2034. Precedence Research.
  3. Clinical Trials Market SIZE, SHARE | GROWTH REPORT [2032]. Fortune Business Insights.
  4. RESCRIPTOR - GSKPro for Healthcare Professionals. GSKPro.
  5. Antiviral Drugs Market Size, Share & Growth Report, 2030. Grand View Research.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.